A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...

Substandard and fake medicines remain a major threat in Africa, risking lives and fuelling drug resistance. A unified ...

Telangana: Aurobindo Pharma has announced that the European Commission (EC) has granted marketing authorization in the ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Needham analyst Gil Blum lowered the firm’s price target on Sarepta (SRPT) to $183 from $202 and keeps a Buy rating on the ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease diagnosis. On Wednesday, a study in Nature suggested that a vaccine for ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

This article examines post-market drug safety, highlighting surveillance mechanisms, regulatory responses, and case studies of approved drugs with hidden risks.

Akebia Therapeutics gets EMA panel support for Xoanacyl to treat high phosphate & iron deficiency in CKD. Read more here.